Drug Approval | August 31, 2021
US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
